In gastric adenocarcinoma, high rates of loco-regional recurrences have been reported even after complete resection, and various studies have been tried to find the role of postoperative adjuvant therapy. Among them, Intergroup 0116 trial was a landmark trial, and demonstrated the definite survival benefit in adjuvant chemoradiotherapy, compared with surgery alone. However, the INT 0116 trial had major limitation for global acceptance of the INT 0116 regimen as an adjuvant treatment modality because of the limited lymph node dissection. Lately, several randomized studies that were performed to patients with D2-dissected gastric cancer were published. This review summarizes the data about patterns of failure after surgical resection and the earlier prospective studies, including INT 0116 study. Author will introduce the latest studies, including ARTIST trial and discuss whether external beam radiotherapy should be applied to patients receiving extended lymph node dissection and adjuvant chemotherapy.

Key Words: Stomach neoplasms; Radiotherapy; Adjuvant

Introduction

The postoperative adjuvant radiotherapy (RT) has been rarely applied to patients with gastric cancer, especially in Eastern country, such as Korea and Japan. The relatively underestimated role of RT in resected gastric cancer mainly comes from the undoubted role of surgery with extended lymph node dissection, the higher metastatic risk than that of loco-regional recurrence after radical surgery and the exaggerated concern of radiation complication. However, even after complete resection, high rates of loco-regional recurrences have been reported,(1–10) and RT combined with chemotherapy have decreased the loco-regional failure and improved the overall survival in some retrospective studies for unresectable or residual disease after surgery.(11,12)

After the introduction of the Gastrointestinal Cancer Intergroup Trial (INT 0116), the largest phase III trial to compare surgery alone versus postoperative chemoradiotherapy (CRT),(13) the adjuvant RT combined with chemotherapy has attracted increasing attention and a series of prospective studies have been published, including Adjuvant Chemoradiation Therapy in Stomach Cancer (ARTIST) trial.(14) However, the INT 0116 trial had a major limitation for global acceptance of the INT 0116 regimen as an adjuvant treatment modality. The limited lymph node dissection (D0 or D1), which was considered as suboptimal surgical resection in Eastern country, was performed in 90% of enrolled patients of the INT 0116 trial. Therefore, the investigation of the efficacy of postoperative CRT in patients with gastric cancer with curative resection and extended D2 lymph node dissection is increasingly important.

This review summarizes the data about patterns of failure after surgical resection and the earlier prospective studies, including INT 0116 study. The author will introduce the latest studies, including ARTIST trial, and discuss the role of adjuvant RT, which is performed in addition to surgery and chemotherapy in patients with...
Patterns of Failure after Surgical Resection

There are several data (Table 1) analyzing the patterns of failure after curative resection, and they could be divided into three groups according to the purpose of analysis. The autopsy data showed the final results of disease failure,(1–3) re-operation data focused to the patients with potentially high risk for recurrence.(4,5) The clinical data(6-10) showed recurrence, which could be detected with clinical examination and imaging studies during the follow-up period. These patterns of failure data need to be interpreted with caution due to different definition of recurrence, different tumor stage and different surgical extension, especially the extent of lymph node dissection.

With the extended lymph node dissection, such as D2 dissection, local recurrence rate can be decreased and the relative rate of liver metastasis or peritoneal seeding can be increased.(9,10) However, loco–regional recurrence developed in many patients after surgical resection and the percentage of loco–regional recurrence without liver metastasis or peritoneal seeding was as high as 20%.

Prospective Randomized Studies for Adjuvant Radiotherapy

The purpose of adjuvant RT is to improve loco–regional control, and combined CRT is a logical postoperative adjuvant treatment for gastric cancer. When combined CRT is applied, 5–fluorouracil (5–FU) is most commonly used chemotherapeutic agent for the radiosensitization effect. The earlier prospective randomized studies before INT 0116 trial were shown in Table 2. Dent et al.(15) randomly assigned 142 patients, according to the disease status, and there was no difference in survival between the concurrent CRT and control groups in either patient cohort. Another study by Moertel et al.(16) randomly assigned 62 patients with poor prognosis gastric carcinoma to receive concurrent CRT or observation. The 5-year survival rate for patients randomized to treatment was 23%, and for those randomized to no treatment, 4% (P<0.05). However, when analyzed according to actual treatment received, the difference was not significant because of small patient numbers. The British Stomach Cancer Group compared the results of surgery alone, adjuvant RT and adjuvant chemotherapy.(17) There was no survival advantage for those patients receiving either adjuvant therapy compared to those undergoing surgery alone, but the loco–regional failure rate was lowest in patient with the adjuvant RT group.

Overall, it is difficult to make conclusion from these studies be-

### Table 1. Patterns of failure after surgical resection

| Recurrence sites       | Clinical (6-10) | Reoperation (4,5) | Autopsy (1-3) |
|------------------------|-----------------|------------------|--------------|
| Loco-regional failure  |                 |                  |              |
| Gastric bed            | 21%             | 55%              | 52–68%       |
| Anastomosis/stump      | 6–25%           | 27%              | 54–60%       |
| Abdominal/stab wound   | -               | 5%               | -            |
| Lymph nodes            | 8–13%           | 43%              | 52%          |

### Table 2. Prospective randomized studies – before INT 0116 trial

| Study             | Stage                        | Group   | Patient number | Treatment RT/CTx | Survival | P-value |
|------------------|------------------------------|---------|----------------|------------------|----------|---------|
| Dent et al.(15)  | T1–3, N1–2, M0               | Control | 31             | -                | No difference | NS      |
|                  | T4 or M1                     | CCRT    | 35             | 20 Gy/5-FU       |          |         |
| Moertel et al.(16)| LN (+), T4                   | Control | 23             | -                | 5-yr SR 4% | <0.05   |
|                  |                              | CCRT    | 39             | 37.5 Gy/5-FU     |          |         |
| BSCG(17)         | Stage II–IVA                 | Control | 145            | -                | 5-yr SR 20% | NS      |
|                  |                              | CTx     | 138            | 45 Gy           |          |         |

RT = radiotherapy; CTx = chemotherapy; CCRT = concurrent chemoradiotherapy; 5-FU = 5-fluorouracil; NS = not-significant; LN = lymph node; SR = survival rate; BSCG = British Stomach Cancer Group; ADR = Adriamycin; MMC = mitomycin-C.
cause of their heterogeneous cohort, small number of patients, failure to standardize surgery and suboptimal dose of RT and 5-FU. Therefore, the INT 0116 trial was very interesting and demonstrated a definite survival benefit with the CRT group in 3-year overall survival rates of 50% and 41% for the postoperatively treated and surgery-alone groups, respectively.(13) According to the updated data with a more than 10-year median follow-up, overall survival and relapse-free survival data demonstrate continued strong benefit from postoperative CRT and the reduction of loco-regional failure may account for the majority of overall relapse reduction.(18) However, only 10% of patients underwent D2 resection and this questioned whether the survival benefit seen in INT 0116 trial was simply compensatory for suboptimal surgery and whether CRT would still be required for patients receiving a D2 resection. In this trial, when subgroup analysis was performed in the D2 resected patients and the overall survival was compared according to treatment arm, and there was no difference between the two groups. However, because the numbers were only 34 and 20 patients in the adjuvant and observation groups, respectively, it was difficult to draw any conclusion.

**Postoperative Chemoradiotherapy in D2-dissected Gastric Cancer**

Although some Western randomized studies(19,20) showed negative results of extended lymph node dissection, several historical data and recent studies(21–24) reported that extended (D2) lymph node dissection leads to better results than limited (D1) lymph node dissection in loco-regional recurrence or overall survival. In addition, gastrectomy with D2 lymph node dissection has become a standard surgical procedure for patients with gastric cancer. Until now, there have been many studies to find adjuvant effect of RT, chemotherapy or CRT after surgery. However, randomized studies done to patient cohort with D2–dissected gastric cancer is uncommon, and lately, a few randomized studies that were performed to patients with extended lymph node dissection were published. According to ACTS–GC and CLASSIC trials,(25,26) adjuvant chemotherapy after curative D2 gastrectomy improved 3-year overall survival and disease-free survival compared with surgery only, and should be considered as a treatment option for patients with operable gastric cancer. In this point, we need to discuss whether there is an additional role of adjuvant RT to patients receiving extended lymph node dissection and adjuvant chemotherapy.

Table 3 shows several gastric cancer studies, which were performed to patients with D2 gastrectomy. Kim et al.(27) reported observational study that showed an advantage in overall survival in patients who underwent a D2 lymph node dissection plus postoperative CRT (INT-0116 scheme) compared with those who underwent D2 lymph node dissection alone. In this observational study, when patterns of failure were analyzed, adjuvant CRT significantly decreased the regional lymph node recurrence rates, and there was no difference in distant metastasis between the two cohorts. Dikken et al.(28) retrospectively compared survival and recurrence patterns in patients from the Dutch Gastric Cancer Group Trial that randomly assigned patients between D1 and D2 lymph node dissection. They concluded that after D1 surgery, the addition of postoperative CRT had a major impact on local recurrence in resectable gastric cancer, and there was no additional effect of adjuvant CRT after D2 surgery.

We know that a prospective randomized trial can provide

### Table 3. Gastric cancer studies performed to patients with D2 gastrectomy

| Study | Stage | Group | Patient number | Treatment RT/CTx | Survival | P-value |
|-------|-------|-------|----------------|-----------------|----------|---------|
| Kim et al.(27) | II–IVA | Control | 446 | - | 45 Gy/FL | MS 63 mo | 0.02 |
| | | CCRT | 544 | 45 Gy/FL | MS 63 mo | 95 mo |
| Dikken et al.(28) | - | Control | 325 | - | 45 Gy/FL, XP | 2-yr LRR 13% | 0.84 |
| | | CCRT | 25 | 45 Gy/FL, XP | 12% |
| ARTIST(14) | IB–IVA | CTx | 228 | XP | 3-yr DFS 74.2% | 0.08 |
| | | CCRT | 230 | 45 Gy/XP | 78.2% |
| Zhu et al.(29) | IB–IVA | CTx | 175 | FL | 45 Gy/FL | MS 48 mo | 0.12 |
| | | CCRT | 205 | 45 Gy/FL | 58 mo |

RT = radiotherapy; CTx = chemotherapy; CCRT = concurrent chemoradiotherapy; FL = fluorouracil, leucovorin; MS = median survival; XP = capecitabine, cisplatin; LRR = local recurrence rate; ARTIST = Adjuvant Chemoradiation Therapy in Stomach Cancer; DFS = disease-free survival.
definite answers to the question whether postoperative RT has a clinical benefit over surgery with extended lymph node dissection and adjuvant chemotherapy. Currently, three such studies aim to answer this question. First, the ARTIST trial(14) randomly assigned 458 patients to chemotherapy arm and CRT arm. The conclusion of ARTIST trial was that the addition of RT to chemotherapy did not significantly reduce recurrence, except lymph node positive patients, and a subsequent trial (ARTIST-II) in patients with lymph node-positive gastric cancer is planned. Interestingly, Zhu et al.(29) recently reported on a similar trial conducted in a Chinese population. They used intensity-modulated radiotherapy (IMRT) as RT technique and observed a significant difference in disease-free survival not only in patients with positive nodes, but in the whole population. In the third study (CRITICS), patients will receive neo-adjuvant chemotherapy, followed by D2 lymphadenectomy, and will be randomly assigned to the three additional courses of chemotherapy or CRT. From these studies, which were performed to the patients with D2-dissected gastric cancer, we can summarize that the addition of RT to surgery and chemotherapy did improve disease-free survival, even though there were no influence on the overall survival. Because the improvement in disease-free survival mainly came from the radiation effect decreasing regional lymph node recurrence, when the subgroup of patients with pathologic lymph node metastasis were analyzed, patients randomly assigned to the CRT arm experienced superior disease-free survival, compared with those who received chemotherapy alone in the ARTIST trial. In the author’s personal experience, the role of RT was to decrease the recurrence of regional lymph nodes (mainly Group 3 lymph nodes including some Group 2 lymph nodes), which could not be dissected even with extended lymph node dissection. Therefore, adjuvant RT should be considered to the patients with D2-dissected gastric cancer with pathologically positive lymph node metastasis, especially to those with advanced N stage. This opinion might be supported by the study(30) that analyzed patterns of regional recurrence after curative gastrectomy and D2 lymph node dissection in patients with stage III (N3) gastric cancer. According to this study, the most prevalent nodal recurrence in patients with advanced gastric cancer was in the nodal basin outside the D2 dissection field.

Conclusions

From the INT-0116 study, we could get the conclusion that the adjuvant CRT demonstrated survival benefit to the patients with sub-optimally resected gastric cancer. When extended lymph node dissection was done, adjuvant chemotherapy improved survival compared with surgery only. Whether or not postoperative RT has a clinical benefit over surgery with extended lymph node dissection and adjuvant chemotherapy is still under investigation. However, ARTIST trial showed that an addition of RT made an improvement in disease-free survival in patients with pathologic lymph node metastasis, and lead to the assumption that the patients with gastric cancer benefit more from CRT than chemotherapy, as more advanced their cancers are. In addition, further investigation to find the highly selected patients who can be beneficial from adjuvant RT will be followed by ARTIST-II trial.

References

1. Mcneer G, Vandenberg H Jr, Donn FY, Bowden L. A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann Surg 1951;134:2-7.
2. Thomson FB, Robins RE. Local recurrence following subtotal resection for gastric carcinoma. Surg Gynecol Obstet 1952;95:341-344.
3. Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol 1986;7:13-18.
4. Wagensteen OH, Lewis FJ, Arhelger SW, Muller JJ, Maclean LD. An interim report upon the second look procedure for cancer of the stomach, colon, and rectum and for limited intraperitoneal carcinosis. Surg Gynecol Obstet 1954;99:257-267.
5. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
6. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990;19:1357-1362.
7. Papachristou DN, Fortner JG. Local recurrence of gastric adenocarcinomas after gastrectomy. J Surg Oncol 1981;18:47-53.
8. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000;87:353-357.
9. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242.
10. Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, et al. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist’s view. Br J Cancer 2004;91:11-17.
11. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867.
12. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group. Cancer 1982;49:1771-1777.
13. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
14. Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.
15. Dent DM, Werner ID, Novis B, Cheverton P, Brice P. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979;44:385-391.
16. Moertel CG, Childs DS, O’Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 1984;2:1249-1254.
17. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994;343:1309-1312.
18. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-2333.
19. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110-112.
20. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaull V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530.
21. Kodama Y, Sugimachi K, Soejima K, Matsusaka T, Inokuchi K. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981;5:241-248.
22. Viste A, Svanes K, Janssen CW Jr, Maartmann-Moe H, Søreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. Eur J Surg 1994;160:497-502.
23. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449-461.
24. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449.
25. Sakuramoto S, Sasaki M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
26. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.
27. Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285.
28. Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol 2010;28:2430-2436.
29. Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol 2012;104:361-366.
30. Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol 2012;104:367-373.